Pegfilgrastim biosimilar - Cinfa Biotech

Drug Profile

Pegfilgrastim biosimilar - Cinfa Biotech

Alternative Names: B 12019; Pegylated granulocyte colony stimulating factor - Cinfa Biotech

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Cinfa Biotech
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Neutropenia

Most Recent Events

  • 03 Dec 2016 Pharmacokinetics, Pharmacodynamics and Adverse event data from a phase I trial in Neutropenia (In volunteers) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 01 Sep 2016 Cinfa Biotech initiates a phase I pharmacokinetics/pharmacodynamics trial in Healthy volunteers in Germany (SC) (NCT02912377)
  • 01 Jul 2016 Cinfa Biotech completes a phase I trial in Neutropenia (In volunteers) in Germany (SC) (NCT02629562)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top